Tag: osé
OSE Immunotherapeutics accentuates its losses in the first half of 2023
(AOF) – OSE Immunotherapeutics announces that as of June 30, 2023, its available cash flow amounted to 15 million euros, ensuring financial visibility until the fourth quarter of 2024. In…
OSE Immunotherapeutics accentuates its losses in the first half of 2023 – 09/27/2023 at 6:18 p.m.
(AOF) – OSE Immunotherapeutics announces that as of June 30, 2023, its available cash flow amounted to 15 million euros, ensuring financial visibility until the fourth quarter of 2024. In…
OSE Immuno presents advances in its research programs at upcoming international conferences CICON International Conference
By Hector Chaunu Published on 09/20/2023 at 7:35 a.m. (Boursier.com) — OSE Immunotherapeutics SA announces that the scientific…
OSE Immunotherapeutics presents advances in its research programs at upcoming international conferences CICON International Conference (Cancer Immunotherapy Conference) SITC Congress (Society for Immunotherapy of Cancer) PEGS Europe (Protein & Antibody Engineering Summit) – 09/20/2023 at 07 :30
Nantes, France – September 20, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the scientific advances from its research programs have been selected for presentation…
OSE Immunotherapeutics: publication of positive phase 3 results of its anti-cancer vaccine – 09/12/2023 at 09:20
(Photo credits: Pixabay – fernando zhiminaicela) (AOF) – OSE Immunotherapeutics announces the publication of positive phase 3 results of its vaccine in patients with lung cancer resistant to immunotherapy in…
OSE Immunotherapeutics: publication of positive phase 3 results of its anti-cancer vaccine
(AOF) – OSE Immunotherapeutics announces the publication of positive phase 3 results of its vaccine in patients with lung cancer resistant to immunotherapy in the peer-reviewed journal “Annals of Oncology”.…
OSE Immunotherapeutics announces new public aid to support its innovation and research programs in the field of RNA Therapeutics – 08/01/2023 at 07:30
Nantes, France – August 1, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the Company has received innovation aid of 200,000 euros from the French…
OSE Immuno: obtaining public aid – 08/01/2023 at 08:00
(CercleFinance.com) – OSE Immunotherapeutics announces that it has received innovation aid of 200,000 euros from the French Government and the Pays de la Loire Region, as part of the ‘France…
OSE Immunotherapeutics: publication on OSE-230 in ‘Frontiers in Immunology’
By Alexandra Saintpierre Published on 07/19/2023 at 6:33 p.m. (Boursier.com) — OSE Immunotherapeutics SA announces the publication,…
OSE Immunotherapeutics: new publication on the OSE-230 antibody – 07/19/2023 at 18:21
(AOF) – OSE Immunotherapeutics announces the publication of the latest results on the pro-resolving monoclonal antibody OSE-230, an innovative new approach in the resolution of severe and chronic inflammation, in…
OSE Immunotherapeutics: new publication on the OSE-230 antibody
(AOF) – OSE Immunotherapeutics announces the publication of the latest results on the pro-resolving monoclonal antibody OSE-230, an innovative new approach in the resolution of severe and chronic inflammation, in…
OSE Immuno: end of recruitment for a phase 1/2 trial – 07/11/2023 at 18:09
(CercleFinance.com) – OSE Immunotherapeutics and the Center Hospitalier Universitaire de Nantes announce the end of patient recruitment in the FIRsT study, a phase 1/2 clinical trial. This is the first…